- FLICNA Podcasts & Journal Club
- Disease Modifying Therapies in Pediatric Onset Multiple Sclerosis
Disease Modifying Therapies in Pediatric Onset Multiple Sclerosis
Language
English
Cost
Free
View recording
This content is only available for our subscribers. Please click here to subscribe to a subscription plan for unrestricted access.
CPD/CME Credits
Moderators:
Prof Dr Kıvılcım Gücüyener Gazi University, Ankara, Turkey
Prof Dr Uluç Yiş Dokuz Eylül University, İzmir, Turkey
Presenters: Dr Çağatay Günay & Dr Didem Soydemir, Dokuz Eylül University, İzmir, Turkey
References
Abdel-Mannan OA, Manchoon C, Rossor T, Southin JC, Tur C, Brownlee W | display-authors=etal (2021) Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Neurol Neuroimmunol Neuroinflamm 8 (4):. DOI: 10.1212/NXI.0000000000001008 PMID: 34021056.
Abdel-Mannan OA, Manchoon C, Rossor T, Southin JC, Tur C, Brownlee W | display-authors=etal (2021) Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Neurol Neuroimmunol Neuroinflamm 8 (4):. DOI: 10.1212/NXI.0000000000001008 PMID: 34021056.
Extract: " with a lower risk of clinical and radiologic relapses in patients compared with injectables"
Evaluation of Teriflunomide in Children and Adolescents With Relapsing MS: TERIKIDS Phase 3 Study Design, Enrollment Update, and Baseline Data (P4.354) Tanuja Chitnis, Marc Tardieu, Brenda Banwell, Kivilcim Gücüyener, Kumaran Deiva, Natalia Skripchenko, Banu Anlar, Miqun Robinson, Rita Deng, Margaux Dupin, Philippe Truffinet, Stephanie Jurgensen, Jeffrey Chavin, Ludwig Kappos Neurology Apr 2018, 90 (15 Supplement) P4.354;